An official website of the United States government Here's how you know

The .gov means it's official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Drugs@FDA: FDA-Approved Drugs

Home | Previous Page

Abbreviated New Drug Application (ANDA): 217183
Company: SCIEGEN PHARMS

Products on ANDA 217183

Drug Name	Active Ingredients	Strength	Dosage Form/Route	Marketing Status	TE Code	RLD	RS
LITHIUM CITRATE	LITHIUM CITRATE	EQ 300MG CARBONATE/5ML	SYRUP;ORAL	Prescription	AA	No	No

Approval Date(s) and History, Letters, Labels, Reviews for ANDA 217183

Original Approvals or Tentative Approvals

Action Date	Submission	Action Type	Submission Classification	Review Priority; Orphan Status	Letters, Reviews, Labels, Patient Package Insert	Notes	Url
03/18/2024	ORIG-1	Approval		STANDARD		Label is not available on this site.

Therapeutic Equivalents for ANDA 217183

LITHIUM CITRATE

SYRUP;ORAL; EQ 300MG CARBONATE/5ML
TE Code = AA

Drug Name	Active Ingredients	Strength	Dosage Form/Route	Marketing Status	RLD	TE Code	Application No.	Company
LITHIUM CITRATE	LITHIUM CITRATE	EQ 300MG CARBONATE/5ML	SYRUP;ORAL	Prescription	No	AA	070755	PAI HOLDINGS PHARM
LITHIUM CITRATE	LITHIUM CITRATE	EQ 300MG CARBONATE/5ML	SYRUP;ORAL	Prescription	No	AA	218036	RUBICON RESEARCH
LITHIUM CITRATE	LITHIUM CITRATE	EQ 300MG CARBONATE/5ML	SYRUP;ORAL	Prescription	No	AA	217183	SCIEGEN PHARMS

Top